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2001 U.S. dollars, then compared and contrasted. RESULTS:
Thirty studies were identiﬁed and reviewed. Seventeen assessed
diagnostic modalities: education and screening (6): dissection
and biopsy (3), follow-up/monitoring (2), chest X-ray (3), CT
and PET scan (3), while 13 evaluated treatments: surgery 
(3), adjuvant interferon (IFN-a) (9), and chemotherapy (1).
Melanoma education and screening programs appears to be cost-
saving or to have CE ratios <$50,000 per QALY saved. Of the
diagnostic, monitoring, and risk stratiﬁcation methods, physical
examination appears more cost-effective than chest x-rays,
abdominal ultrasound, CT scans, PET scans, and liver function
tests. The CE of therapeutic options depends on disease stage,
comorbidity, and other factors. All nine IFN-a studies across
multiple countries and research designs consistently present
favorable CE ratios, which improve as study time horizon is
extended. Among other therapies, Mohs micrographic surgery
appears more cost-effective than surgical excision and resection.
Radiosurgery combined with radiotherapy also appears to be
cost-effective compared to radiotherapy alone in at least some
subset of patients. Finally, the CE of experimental treatment such
as isolated limb perfusion, vaccines, and gene therapies, has not
been studied. CONCLUSIONS: The literature provides valuable
information to policy makers seeking to reduce the economic
burden of melanoma, most notably with respect to physical
examination and interferon. As new diagnostic and therapeutic
modalities become available, research is needed on their eco-
nomic value.
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OBJECTIVES: Results from the ATAC trial indicated that anas-
trozole was superior to tamoxifen in terms of disease free sur-
vival in the adjuvant treatment of postmenopausal women with
hormone receptor-positive (HR+) EBC. Using updated 47-month
data (Cancer 2003;98:1802–10), we calculated the direct
medical costs and incremental cost effectiveness ratio (ICER) per
life year gained (LYG) for managing this group for anastrozole
compared with tamoxifen within the UK NHS setting.
METHODS: Using the updated ATAC data, we developed a
probabilistic Markov model, which projected outcomes for both
anastrozole and tamoxifen to 25 years (lifetime horizon) by
extrapolating pooled Kaplan-Meier curves. General mortality
data were obtained from UK national statistics. It was assumed
that anastrozole and tamoxifen would be given for ﬁve years
maximum and that recurrence rates after this treatment period
would be equivalent in the two groups—a conservative
approach. Resource utilization data associated with treating
adverse events were obtained from published literature. Other
resource utilization data were estimated from interviews with six
UK physicians. Unit costs in GBP were obtained from 2002 NHS
reference costs and 2003 drug costs (BNF). Costs and beneﬁts
were discounted at 6% and 1.5%, respectively. RESULTS: Con-
sidering a cohort of 1000 patients modeled for 25 years, anas-
trozole was estimated to lead to 184 discounted LYG at an
additional cost of £2.1 million. Consequently, the discounted
ICER of anastrozole compared with tamoxifen was estimated to
be £11,747/LYG (95% CI £1,946–£21,984). Furthermore,
acceptability curves showed that the estimated cost/LYG at 25
years was <£20,000 with a probability >90%. The result com-
pared favorably with commonly accepted thresholds for cost-
effectiveness of other cancer drugs and was robust to all para-
meters (including adverse events) tested in sensitivity analyses.
CONCLUSIONS: Based on these ﬁndings, anastrozole should be
a cost-effective alternative to tamoxifen for the adjuvant treat-
ment of postmenopausal women with HR+ early breast cancer.
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OBJECTIVES: We examined the cost-effectiveness (CE) of treat-
ment with adjuvant high-dose Interferon-alpha (IFN-alpha)
given in melanoma patients at high-risk for recurrence from a
program perspective. METHODS: A continuous-time Markov
model with nine health states (no evidence of disease, local-
regional recurrence, ﬁrst salvage local-regional recurrence,
second local-regional recurrence, ﬁrst distant recurrence, sal-
vaged distant recurrence, second distant recurrence, death from
melanoma, and death of other causes) was designed to assess the
CE of IFN-alpha treatment compared to no adjuvant treatment.
Estimates of costs (inﬂated to 2002), utilities for health states,
and treatment beneﬁts were retrieved from published literature.
A non-informative prior was used for the survival parameters
and patient-level data was simulated with survival parameters
retrieved from published literature. To quantify the tradeoff
between IFN-alpha toxicity and survival, net beneﬁts were 
calculated as potential savings in quality-adjusted life years
(QALYs). Average costs and beneﬁts were derived from the inte-
gration over unknown patient parameters. The posterior incre-
mental cost-effectiveness ratio (ICER) was then simulated as the
difference in average cost divided by the difference in average
effectiveness. RESULTS: The posterior mean estimate of the
incremental costs of the IFN-alpha was $37,000 and the poste-
rior mean estimate of the incremental beneﬁts was 0.75 QALY.
The estimated posterior mean ICER was $50,300/QALY with
standard deviation $183/QALY. The acceptability curve (CEAcc)
shows that the probability that IFN-alpha treatment will lead to
improved life expectancy is one. CONCLUSIONS: IFN-alpha
treatment is more costly and more effective based on simulated
patient-level data. With patient-level data, we will be able to
provide information on the variability of model parameters and
produce the acceptability curve using the current model.
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OBJECTIVE: To investigate the cost of asthma care for enrollees
in the Medicare program and the effect of voluntary outpatient
prescription drug coverage on Medicare covered asthma expen-
ditures. METHODS: Data were drawn from the 2001 Medicare
Current Beneﬁciary Survey, a nationally representative sample of
the Medicare population, which includes data on health care
expenditures and individual characteristics such as health status.
Sample size was 13,998, including 1,310 persons with asthma.
We used regression analysis to examine differences in expendi-
tures between those with and without asthma, controlling for
other chronic illnesses, self-rated health, age, gender, activity of
